Portage Biotech

@IntensityInc Portage congratulates Intensity Therapeutics on their spotlight presentation at #SABC23. The data on systemic T-cell repertoire is certainly exciting for a locally administered therapy. We look forward to seeing you advancing this into late phase studies.

Listen to our CFO, Allan Shaw on this #BusinessOfBiotech episode, where he & host @mattpillar discuss cash management and "runway preservation" for new & emerging #biopharma companies, #financing during clinical trials, managing funds and more here: brnw.ch/21wBHzH $PRTG

#ICYMI our CEO, Dr. Ian Walters was featured as an expert panelist along with other industry leaders at #BIO2023 to discuss #CheckpointInhibitors & progress in the #ImmunoOncology space, moderated by @Angus_Fierce of @FierceBiotech. Learn more here: brnw.ch/21wBDcM

Our CEO, Dr. Ian Walters, weighed in on the influence that an increase in patient-centric concern has on Portage’s work with #ImmunoOncology treatments in this @PharmasAlmanac roundtable. Read more about our #PrecisionOncology approach here: fal.cn/3AyBY

Check out our CEO, Ian Walters, M.D. featured in “The State of the Union in Cancer Innovation” piece by @PM360online discussing exciting developments in precision #immuno-onoclogy including Portage’s current clinical programs: fal.cn/3zTfg

Dr. Nicholas Coupe, PI on our Phase 1/2 trial, discussed the investigation of our PORT-2 #iNKT engager in patients with advanced #melanoma or metastatic #NSCLC in this @OncLive video. Learn more here: fal.cn/3zRfX

Our CFO, Allan Shaw, connected with @WayneKoberstein of Life Science Leader to discuss navigating the new bio funding challenges and risks. Read more about his thoughts on collaborations and considerations here: fal.cn/3zN9r

Congratulations to our collaborators, @IntensityInc, on their successful upsized IPO! This is the second IPO from the Portage universe & we’re grateful to see the public markets are being more open to #biotech offerings! $BHVN $PRTG Read more here: fal.cn/3zAXJ

We’re excited to announce that we have dosed the first patient in our Phase 1a trial evaluating our adenosine 2A receptor inhibitor in select solid tumors. We look forward to exploring our next-gen approach to target the #adenosine pathway. Learn more: fal.cn/3zoW9

While at #ASCO23, our CEO Dr. Ian Walters spoke with @OncologyTube about Portage’s updated data on its #iNKT engager for the treatment of #melanoma and #NSCLC. Learn more about the #clinicaltrial results here: fal.cn/3zhvu

The #adenosine space is heating up with its own conference focused on novel ways to treat #cancer. Our CEO Dr. Ian Walters will chair day one of the Adenosine-Pathway Targeted Cancer Immunotherapy Summit & guide discussion on clinical progress. More here: fal.cn/3zftE

Our CFO Allan Shaw joined #BusinessOfBiotech podcast host @mattpillar to discuss the #InflationReductionAct and its implications for the biotech industry and the patients we work to serve. Listen to the episode here: bit.ly/3CbByEj @BioProcessOL

We’re pleased to share updated interim data on our lead #iNKT engager in a Phase 1/2 study for the treatment of #melanoma and #NSCLC at #ASCO23. For more details on the poster, click here: bit.ly/3qogjN0

We’re excited our CEO, Dr. Ian Walters, will serve as expert panelist discussing the future of immune #CheckpointInhibitors in an #oncology panel at #BIO2023 moderated by @Angus_Fierce of @FierceBiotech Our team will also be in attendance. More here: bit.ly/3WJoJum

Check out this episode of @molecule2markt podcast, featuring our CEO Ian Walters! Ian discusses his background in the industry, along with Portage’s business model and progress in the clinic. Learn more about what makes Portage unique here: bit.ly/426vsA1

Our CFO, Allan Shaw, was recently a guest on @molecule2markt podcast, where he discusses his views on the state of the market and potential opportunities for companies to be capital-efficient. Listen here: bit.ly/3n1jHMo

We’re excited to be presenting an update on our study of PORT-2 (#iNKT engager) for the treatment of #NSCLC & #melanoma at @ASCO Please stop by the session or contact us after the meeting for more information: bit.ly/41EofHE #ASCO23

Our CEO Dr. Ian Walters spoke with @GENbio about his career evolution from a practicing physician to a biotech industry leader. Read more about Ian and other biotech executives who began as Ph.D.s and M.D.s here: bit.ly/3GmEoca

#ICYMI Lawrence Fong, M.D., & Sumit Subudhi, M.D., Ph.D, participated in our KOL event on targeting the #adenosine pathway to treat #cancer. Learn more about this unique pathway & why we’re excited to continue studying these programs in clinical trials: bit.ly/3FoDqvt

#ICYMI we hosted a KOL event on targeting #adenosine for cancer & the potential for our next-gen inhibitors to improve treatment outcomes. Watch the recording to learn about current data with insights from Sumit Subudhi, M.D., Ph.D. & Lawrence Fong, M.D.: bit.ly/3FoDqvt